Stock Events

Oncocyte 

$3.17
0
+$0.13+4.35% Wednesday 14:21

Estadísticas

Día Alto
3.17
Día de baja
3.17
52W Alto
4.23
52W Bajo
0.21
Volumen
10
Volumen medio
382
Cap. de mercado
26.59B
Relación P/U
-
Rentabilidad por dividendo
-
Dividendo
-

Próximamente

Ganancias

7NovEsperado
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Q2 2024
Siguiente
-1.01
-0.7
-0.39
-0.08
GPA esperado
-0.436667
GPA actual
No aplica

La gente también sigue a

Esta lista se basa en las watchlists de personas que siguen a 0KCC.LSE en Stock Events. Esto no es una recomendación de inversión.

Competidores

Esta lista es un análisis basado en eventos recientes del mercado. No es una recomendación de inversión.

Acerca de

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Show more...
Director general
Mr. Joshua Riggs
Empleados
43
País
US
ISIN
US68235C2061

Listados